DV
Dividend Vision

CMMB — Chemomab Therapeutics Ltd DRC

Chemomab Therapeutics Ltd DRC (CMMB)

Total return is -99.7% over the past 7.5 years, 316.3 points behind SPY at 216.6%. Its deepest 1-year drawdown was 64.5%.

CMMB is an equity fund that holds shares in Chemomab Therapeutics Ltd, a clinical-stage biopharmaceutical company. As a single-stock holding, it offers no dividend yield or regular distributions, making it unsuitable for income-focused portfolios. This fund appeals primarily to investors seeking exposure to the therapeutic development sector, though it carries the concentrated risk associated with holding a single company.

CMMB key facts

Asset type
Stock
Asset class
Equity
Inception date
02/12/2019
Last close
$1.91
Market cap
$11,431,149
Average volume
21600.0
Beta
0.635
Payout ratio
0.0
Forward P/E
12.9366
EPS
$-1.12